Bristol-Myers submits ipilimumab BLA

Bristol-Myers Squibb Co. (NYSE:BMY) said that in late June it submitted a BLA to FDA for ipilimumab to treat metastatic melanoma in pre-treated patients. The human mAb against CTLA-4 receptor is under...